Big Money Not In Dermira (NASDAQ:DERM), Sentiment at 0.98

Dermira, Inc. (NASDAQ:DERM) Corporate Logo

Positions for Dermira (NASDAQ:DERM)

In 2018 Q2 Dermira (NASDAQ:DERM) big money sentiment decreased to 0.98, filings reveal. So its down -0.10, from 2018Q1’s 1.08. 53 active investment managers increased or started new positions, while 54 sold and decreased their holdings in Dermira so the sentiment worsened. Funds own 33.73 million shares, down from 34.74 million shares in 2018Q1. Funds holding Dermira in top 10 was flat from 0 to 0 for the same number . In total 22 funds closed positions, 32 reduced and 32 increased. Also 21 funds bought new Dermira stakes.

Most Dermira Shareholders

As of 2018 Q2 Nea Management Company Llc has 1.51% invested in Dermira. Dermira’s shareholder Venbio Select Advisor Llc owns 1.84 million shares as of 2018 Q2. First Midwest Bank Trust Division reported 328,170 shares. The Maryland-based fund Rock Springs Capital Management Lp have invested about 0.21% of the active investment manager’s stock portfolio in Dermira. The Massachusetts-based fund Fernwood Investment Management Llc holds 27,400 shares or 0.14% of their US long stock exposure.

Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States.The firm is valued at $458.70 million. The companyÂ’s late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne.Last it reported negative earnings. It has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia.

DERM is touching $10.89 during the last trading session, after decreased 1.18%.Dermira, Inc. has volume of 430,384 shares. Since December 8, 2017 DERM has declined 58.55% and is downtrending. The stock underperformed the S&P 500 by 74.17%.

On February, 28. Investors wait Dermira, Inc. (NASDAQ:DERM) to announce its quarterly earnings, as reported by RTT. EPS of $-1.80 is 34.33 % down from 2017’s $-1.34 EPS. Wall Street now predicts 13.92 % negative EPS growth despite Dermira, Inc. previous quarter’s EPS of $-1.58.

First Republic Investment Management reported 0% of its capital in Dermira, Inc. (NASDAQ:DERM). Metropolitan Life Insurance Ny holds 0% of its capital in Dermira, Inc. (NASDAQ:DERM) for 12,912 shs. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 1,873 shs. Balyasny Asset Mgmt Ltd Liability Corp invested in 0% or 12,310 shs. 102,228 are owned by Engineers Gate Manager Lp. Sei Invests stated it has 0% in Dermira, Inc. (NASDAQ:DERM). Jump Trading Limited Liability Co reported 0.01% stake. Bnp Paribas Arbitrage Sa holds 1,183 shs or 0% of its capital. Blackrock Inc stated it has 3.68M shs. American Gp Incorporated holds 0% or 22,682 shs. Barclays Public Limited Company stated it has 0% of its capital in Dermira, Inc. (NASDAQ:DERM). Price T Rowe Assocs Md reported 0% stake. Ameritas Ptnrs Incorporated invested in 3,345 shs. Savings Bank Of New York Mellon Corporation has 0% invested in Dermira, Inc. (NASDAQ:DERM) for 223,759 shs. Venbio Select Advisor Limited Liability Company, California-based fund reported 1.84M shs.

Dermira, Inc. had 1 sale and 4 insider buys since June 18, 2018. This’s net activity of $424,489. Fust Matthew K also sold $55,000 worth of Dermira, Inc. (NASDAQ:DERM) on Friday, October 19.

For more Dermira, Inc. (NASDAQ:DERM) news announced briefly go to:,,, or The titles are as follows: “Dermira to Present at Evercore ISI HealthCONx Conference – Nasdaq” announced on November 19, 2018, “CMTA Fast Tracks NDA Filing, USNA In Good Health, DERM To Report Data In Apr. – Nasdaq” on October 24, 2018, “Dermira Initiates Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis – GlobeNewswire” with a publish date: January 31, 2018, “SA Interview: Biotechnology Investing With Juggernaut Capital – Seeking Alpha” and the last “Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update – GlobeNewswire” with publication date: May 03, 2018.

Dermira, Inc. (NASDAQ:DERM) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.